Pediatr Infect Dis J by Jin, Haoxing et al.
Long-term Visual and Ocular Sequelae in Patients with 
Congenital Cytomegalovirus Infection
Haoxing Jin, MD1, Gail J. Demmler-Harrison, MD2,4, David K. Coats, MD2,3, Evelyn A. 
Paysse, MD2,3, Amit Bhatt, MD2,3, Jane C. Edmond, MD2,3, Kimberly G. Yen, MD2,3, Paul 
Steinkuller, MD2,3, and Jerry Miller, MS, PhD2 for The Congenital CMV Longitudinal Study 
Group2,4
1School of Medicine, Baylor College of Medicine, Houston, TX
2Texas Children’s Hospital, Houston, TX
3Department of Pediatric Ophthalmology, Baylor College of Medicine, Houston, TX
4Department of Pediatrics, section of Infectious Disease, Baylor College of Medicine, Houston, TX
Abstract
Background—Cytomegalovirus (CMV) is the most common congenital viral infection in the 
United States. Visual and ocular sequelae in adolescents and adults who are congenitally infected 
with CMV have not been well studied. Better understanding of the long-term visual and ocular 
sequelae can help with early detection, intervention, and appropriate educational accommodations.
Methods—This study evaluated 237 (77 symptomatic, 109 asymptomatic, and 51 control) 
patients who underwent a series of age-appropriate ophthalmologic, audiologic, and 
neurodevelopmental examinations from 1982 to 2013. The frequency and etiology of visual 
impairment and other non-ophthalmologic findings were recorded for each patient. 
Ophthalmologic findings were tabulated and risk factors for abnormalities were analyzed.
Results—Fourteen of the 77 (18.2%) symptomatic and none of the asymptomatic and control 
subjects had severe visual impairments (p ≤ 0.006). Moderate visual impairment did not differ 
between symptomatic and asymptomatic subjects. Three asymptomatic subjects had retinal scars. 
The most common visual or ocular sequelae in the symptomatic group were strabismus (23.4%), 
chorioretinal scars (19.5%), cortical visual impairment (14.3%), nystagmus (14.3%), and optic 
nerve atrophy (11.7%). Three symptomatic patients had delayed visual deterioration due to later 
occurring retinal disorders: peripheral retinal scar, rhegmatogenous retinal detachment, and Coats’ 
disease.
Conclusion—Symptomatic CMV patients experienced more ophthalmologic sequelae and 
significantly worse visual outcomes than asymptomatic CMV and control patients. Later occurring 
retinal disorders were found in symptomatic patients, and there is no clear evidence that CMV can 
reactivate in the retinas of children who were congenitally infected. Major risk factors for severe 
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visual impairment included symptomatic status, optic nerve atrophy, chorioretinitis, cortical visual 
impairment, and sensorineural hearing loss.
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Introduction
Cytomegalovirus (CMV) is the most common congenital viral infection in the United States, 
affecting approximately 1% of all live births (30,000–40,000) annually.1 Eighty to 85% of 
congenitally infected patients do not readily exhibit clinical symptoms of CMV infection at 
birth.1 The remaining 15–20% of the congenitally infected patients, described as having 
symptomatic congenital CMV infection, often show one or more clinically observable 
abnormalities, which include microcephaly, jaundice, hepatosplenomegaly, petechiae, 
hearing loss, and chorioretinitis.1 The most commonly appreciated and most commonly 
studied long-term sequelae of congenital CMV infection is progressive sensorineural hearing 
loss. Neurodevelopmental disabilities are also well documented. The most commonly-
reported visual and ocular sequelae in congenital CMV infection are chorioretinitis, optic 
atrophy, strabismus, and cortical visual impairment.1–7 However, the long-term visual and 
ocular outcomes of congenital CMV infection are not as well studied or as well known.
Determining the prevalence and onset of visual and ocular sequelae in patients congenitally 
infected with CMV is extremely important because early detection can lead to early 
intervention and appropriate educational accommodations. Long-term, comprehensive 
prospective studies in patients who are congenitally infected with CMV are lacking within 
the past two decades. Prior publication on ophthalmologic findings in patients with 
congenital CMV infection were published more than a decade ago.3,6,8 The latest 
publication on congenital CMV outcomes in Sweden and United Kingdom was published in 
2013 focused on the hearing and neurodevelopmental aspects on the disease, and reported 
one case of optic atrophy.9 The purpose of this study was to update our previous findings,3 
to determine the frequency and type of visual and ocular abnormalities through childhood, 
adolescence and into early adulthood, and to report associated non-ophthalmologic CMV 
sequelae as potential risk factors for visual and ocular sequelae in a study population that has 
been followed for more than 30 years.
Materials and Methods
The study population comprised 237 infants and children who enrolled in a long-term, 
prospective congenital CMV study (The Houston Congenital CMV Longitudinal Study) 
since 1982. During 1982–1992, 32,543 newborns delivered at Women’s Hospital of Texas (a 
private hospital that served a primarily white, middle to upper socioeconomic population), 
Houston TX, were screened for congenital CMV infection via urine culture collected within 
3 days of life, as described previously.10 Of the asymptomatic subjects, 92 were from the 
screened population and 17 were referred from other sources. Four of the symptomatic cases 
were from the screened population and 73 were referred from other sources. Of the controls, 
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44 were from the screened population, and 7 were referred. Earlier visual and ocular exam 
findings were first described by Coats, et al.3 Congenital CMV infection diagnosis required 
isolation in cell viral culture of CMV from the urine of the infant within the first 3 weeks of 
life as described previously.3 Symptomatic congenital CMV infection was defined as the 
presence of one or more of the clinical symptoms associated with CMV infection at birth, 
after exclusion of other causes of congenital infection. The clinical symptoms associated 
with symptomatic congenital CMV infection classification at birth were low birth-weight 
adjusted for gestational age (small for gestational age (SGA)), generalized petechial rash, 
hepatomegaly, splenomegaly, jaundice at birth, microcephaly (< Lubcenko 10th percentile), 
seizures, and thrombocytopenia.1,4 Asymptomatic congenital CMV infection was defined as 
positive CMV urine cell viral cultures but with no readily observable clinical manifestation 
of disease at birth, and control subject patients were defined by a normal newborn exam and 
a negative urine cell viral CMV culture in the first three weeks of life. All controls were 
CMV-negative at birth, and were selected among screened newborns or referred into the 
study.
Patients underwent serial age-appropriate, multidisciplinary evaluations, consisting of 
ophthalmologic examinations by pediatric ophthalmologists, neurodevelopment evaluations, 
audiologic screening, and urine and salivary CMV viral cell cultures. Ophthalmologic 
examinations were scheduled at 4–6 weeks, 9–12 months, 18–24 months, 3–3.5 years, 4.5–5 
years, 3rd – 4th grade, 7th–8th grade, junior or senior year of high school, and at college 
graduation age.
From 1982 to 1994 only symptomatic CMV patients received ophthalmologic exams, but 
beginning in 1995, asymptomatic CMV and control patients were also included because of 
reports of late onset or reactivation of chorioretinitis in children with asymptomatic 
congenital CMV infection.12 Ophthalmologic examination included measurement of best 
corrected visual acuity, pupils, ocular adnexa, anterior segment, posterior segment, visual 
fields, extraocular motility and alignment, tonometry, and dilated funduscopic examination 
with cycloplegic refraction.
Vision was classified as normal, moderate impairment, and severe impairment.13 Normal 
vision was defined as best corrected acuity better than or equal to 20/40 on optotype visual 
acuity testing in each eye for those patients who were able to cooperate, or fix and following 
on a near object for nonverbal and pre-verbal children. The best-corrected vision required to 
obtain a driver’s license is 20/40. Moderate visual impairment was defined as best corrected 
visual acuity better than or equal to 20/200 and worse than 20/40, or the presence of fixation 
on a near object but no following. Legal blindness is defined as best-corrected vision less 
than 20/200. Severe impairment was defined as vision worse than 20/200, no demonstrable 
fix and follow behavior, or no reaction to light. Progression of chorioretinal lesions was used 
to describe an ongoing lesion that was worsening or expanding, while reactivation referred 
to the activation of a previously quiescent or healing lesion. Chorioretinitis was defined as 
acute and active retinal lesion seen by the pediatric ophthalmologist, whereas chorioretinal 
scars were inactive form of the chorioretinal lesions.
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Statistical analysis was done using SPSS software (IBM Corp. Released 1989 & 2015. IBM 
SPSS Statistics for Windows, Version 23. Armonk, NY: IBM Corp.). Continuous variables 
were compared between subject groups with t-tests and statistical significance assessed by 
Pearson Chi-square or Fisher’s Exact Test. Kaplan-Meier analysis was used to graph the 
development of non-normal visual acuity for all subjects. Categorical variables were 
compared using Chi-square tests for differences in proportions. All p-values were two-sided.
This study was conducted with approval of the Baylor College of Medicine Institutional 
Review Board for Research on Human Subjects.
Results
The demographic data of the longitudinal CMV study patients, estimated gestational age, 
birth weight, age at the most recent eye exams, and the average number of eye exams were 
tabulated in Table 1. The majority of study patients were white. There was no significant 
difference in race among the three CMV disease status groups. There were significantly 
more males in the control group compared to symptomatic group (p = 0.027). The average 
age at the most recent eye exam was significantly younger in symptomatic group (p < 
0.001), which also received a significantly higher number of eye exams (p < 0.001). 
Symptomatic CMV patients had lower estimated gestational age and birth weight than did 
asymptomatic and control patients (p ≤ 0.002).
Severe visual impairment was found in 10 (13.0%) symptomatic patients, and was caused by 
optic nerve atrophy (6/10), chorioretinitis (6/10), cortical visual impairment (7/10), and 
chronic retinal detachment (1/10) (Table 2). All abnormalities leading to severe visual 
impairment were diagnosed before the age of 18 in both the symptomatic and asymptomatic 
groups (Figure 1). Two patients’ chorioretinal lesions had progressed during follow up 
shortly after birth. One had an increase in the number of chorioretinal lesions from one to 
four within the first month of life with an advancement in the borders of the first lesion. This 
patient’s lesions became stable after the neonatal period. The second patient experienced 
advancement in size of the two chorioretinal lesions during follow up in the second, fifth, 
and 24 months of life; which became stable thereafter.
Optic nerve atrophy was a significant cause of severe visual impairment in the symptomatic 
group, as it was noted in 8 (10.4%) symptomatic, 0 asymptomatic, and 1 (2%) control 
patients. Optic nerve atrophy was first diagnosed at the average age of 5.4 years for 
symptomatic patients and at the age of 8.8 years in the control patient. The one control 
patient had optic nerve atrophy secondary to Leber hereditary optic neuropathy, an unrelated 
condition. Chorioretinal scars, which usually follow active chorioretinitis, were seen more 
frequently in symptomatic CMV patients than in asymptomatic CMV and control patients 
(Table 2). Later occurring retinal disorders (peripheral retinal scar, rhegmatogenous (trauma-
induced) retinal detachment, and Coats’ disease) were detected in three symptomatic 
patients. The peripheral retinal scar could be a new onset lesion, but was most likely existing 
scar that was missed on previous exams due to poor cooperation. The rhegmatogenous 
retinal detachment was likely trauma related, and the Coats’ disease was diagnosed based on 
vascular changes consistent with the disorder after examination by a retinal specialist. While 
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chorioretinal scars were unilateral or bilateral in the symptomatic group, only unilateral 
scars were seen in asymptomatic and control groups (Table 2). One control patient had a 1/8 
disc-diameter stable peripheral chorioretinal pigmented scar with normal visual acuity. 
Cortical visual impairment (CVI) was noted in 11 (14.3%) symptomatic patients at the 
average age of 5.1 years, and in none of the asymptomatic patients or controls (Table 3). 
Two of the 11 CVI patients received and were noted to have abnormal visual evoked 
potentials.
Strabismus was more common (23.4%) in the symptomatic than in asymptomatic (1.8%) or 
control (3.9%) groups (Table 3), and they were detected at the average ages of 4.5, 10.9, and 
15.8 years, respectively. Of the symptomatic patients with strabismus, exotropia was five 
times more common than esotropia. Nystagmus was detected at the average age of 7.9 years 
and was only found in symptomatic patients, and it was highly correlated with cortical visual 
impairment (p < 0.001) and severe visual impairment (p < 0.008). There were no statistically 
significant differences among the three disease status groups in mean cycloplegic refraction, 
prevalence of amblyopia, and anterior segment findings (Table 3). The five cases of anterior 
segment findings noted in the symptomatic group were corneal stromal scar, anterior polar 
cataract, microcornea, superficial punctate keratitis, and iris heterochromia. The three 
anterior segment findings in the asymptomatic group were iris heterochromia, anterior 
stromal scar, and limbal pannus. The anterior segments findings in the two control patients 
were Mittendorf’s dot, which is a normal embryonic remnant, and superficial stromal 
opacities, which is a benign finding. Five patients (6.5%) had abnormal optic nerve cupping 
(cup-to-disc ratio > 0.5) in the symptomatic group versus only one (0.9%) in the 
asymptomatic (p = 0.083) and none in the control groups (p = 0.156). There was a slightly, 
but statistically significant higher prevalence of astigmatism in the symptomatic group 
compared to the asymptomatic group (p = 0.049).
Non-ocular findings, including sensorineural hearing loss (SNHL), microcephaly, abnormal 
brain CT imaging, and intracranial calcifications were significantly higher in the 
symptomatic CMV group than in the asymptomatic CMV group (Table 4). SNHL in 
particular was highly associated with the six leading ophthalmologic findings: optic nerve 
atrophy, nystagmus, cortical visual impairment, retinal scars, strabismus, and severe visual 
impairment.
Discussion
Ophthalmologic manifestations of congenital CMV infection can be classified according to 
the affected anatomical regions – anterior segment, posterior segment, and cortical visual 
pathways. There was a similar prevalence and severity of anterior segment findings among 
the three groups, suggesting CMV may have played a limited role in damaging non-neuron-
associated cell lines.12 Anterior segment findings in our subjects, such as corneal stromal 
scar, anterior polar cataract, microcornea, superficial punctate keratitis, and iris 
heterochromia were therefore unlikely to be caused by congenital CMV infection, and also 
were not associated with significant visual impairment.12 In contrast, the posterior segment 
of the eye was affected most severely by congenital CMV infection, resulting in optic nerve 
atrophy and chorioretinal scars, and subsequent severe decrease in visual acuity. In addition, 
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posterior visual pathways were also severely affected by CMV, causing cortical visual 
blindness.3,11,14,15,17 While the exact pathogenesis of CMV causing visual impairment is 
unknown, clinical evidence reveals high tropism of CMV to nerve cells.17 In addition, since 
symptoms at birth are associated with an earlier maternal infection during pregnancy,18, 19 
we highly suspect that the virus’s high tropism to rapidly developing neurons during the first 
trimester of pregnancy is responsible for the neuron-related damages as seen in retina scar, 
optic nerve atrophy, cortical visual impairment, microcephaly, and sensorineural hearing 
loss. The high prevalence of strabismus in symptomatic patients most likely developed from 
optic nerve atrophy and chorioretinal scars. Nystagmus likely occurred from CMV’s direct 
involvement in the central nervous system, or was associated with early onset bilateral 
moderate to severe vision impairment. Although four cases (3.7%) of chorioretinal scars 
were seen in the asymptomatic group, the lesions were in the periphery and did not cause 
noticeable visual impairment.
The presence of clinical symptoms of CMV infection at birth, and especially that of 
microcephaly, was the most important predictor for developing severe visual impairment in 
patients congenitally infected with CMV.16 In addition, SNHL was also associated with 
decreased visual acuity (p = 0.028) in symptomatic patients. The combination of these two 
sensory disorders would potentially make communication with these patients a challenge.
Progressive hearing loss is common in symptomatic congenital CMV. However, there have 
been limited reports on late onset, progressive, or reactivation of CMV chorioretinitis in 
congenital CMV in otherwise normal and immunocompetent individuals,2, 11, 20 which is 
probably due to the rarity of the event and the limited follow up time in most studies. The 
three patients who were noted to have later occurring retinal disorders were all symptomatic 
at birth who developed other visual and ocular and developmental sequelae. Although the 
possibility of late onset or reactivation of CMV chorioretinitis cannot be excluded, two cases 
had plausible alternative diagnoses (trauma and Coats’ Disease), and the one case of later 
detected retinal scar was located in the far periphery, and was likely missed on previous 
exams. It has been thought that chorioretinal lesions caused by congenital CMV infection 
rarely progress postnatally,21 and there is no clear evidence from the present study that CMV 
in the retina can reactivate in congenitally infected patients.
Symptomatic patients who do not experience retinal or posterior visual pathway lesions 
early in life should expect to have similar visual acuity to that of individuals with 
asymptomatic congenital CMV and uninfected controls.
Unlike SNHL, which can be late-onset and is commonly progressive in asymptomatic 
congenital CMV infection,22,23,24–27 the chorioretinitis associated with asymptomatic 
congenital CMV infection did not progress and visual performance was comparable to that 
of normal healthy controls into young adulthood.21
One limitation of our study was ophthalmologic examination in younger patients was 
difficult, which made examining the peripheral retina challenging at times. In addition, our 
study sample came from a private maternity hospital, which served at the time a primarily 
white, middle to upper class, and educated socioeconomic population of the community. 
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Future studies with more diverse sample population may make the clinical findings more 
generalizable.
In summary, strabismus, optic atrophy, cortical visual impairment, and chorioretinitis were 
the most common long-term visual and ocular findings causing moderate to severe visual 
impairment in subjects with symptomatic CMV status at birth. Progressive chorioretinitis 
was rare and only occurred in two patients and was limited to early in life. Later-detected 
retinal disorders were seen in the present study in symptomatic CMV patients; however, 
since these late onset retinal lesions had plausible alternative diagnoses by specialists, there 
was no clear evidence that congenital CMV infection can lead to late onset or reactivation of 
chorioretinitis.
Given our findings, we recommend yearly ophthalmologic examination in patients with 
symptomatic congenital CMV infection who have ocular or visual disorders detected in 
infancy. Asymptomatic patients, newborns who fail their newborn hearing screen, and those 
who were identified to be congenitally infected with CMV via a congenital CMV screening 
program should also receive a baseline ophthalmologic examination. An abnormal baseline 
ophthalmologic examination warrants annual follow up whereas if the exam is normal, they 
can be followed as clinically indicated by signs and symptoms of visual problems.
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Figure 1. 
Kaplan Meier analysis showing age of last acquisition of abnormal visual acuity as 
measured by the best-corrected vision.
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